Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,750,000 shares, a decrease of 13.8% from the January 15th total of 3,190,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is currently 2.1 days. Approximately 3.3% of the company's shares are short sold.

Compass Therapeutics Price Performance

Shares of CMPX stock traded up $0.21 during trading hours on Wednesday, reaching $3.38. 902,798 shares of the stock were exchanged, compared to its average volume of 2,182,983. The business's fifty day moving average is $2.34 and its two-hundred day moving average is $1.84. The firm has a market capitalization of $464.37 million, a P/E ratio of -9.12 and a beta of 1.17. Compass Therapeutics has a 12-month low of $0.76 and a 12-month high of $4.08.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday. They set an "overweight" rating and a $12.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Jefferies Financial Group lifted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. Leerink Partners lowered shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, Leerink Partnrs cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $11.29.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently modified their holdings of the company. Enavate Sciences GP LLC purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth $11,293,000. Tang Capital Management LLC raised its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after buying an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC lifted its holdings in Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after buying an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after acquiring an additional 356,352 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after acquiring an additional 227,864 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.